A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity

Description

The main purpose of this study is to learn more about the safety and efficacy of investigational tirzepatide doses in participants with Type 2 diabetes and obesity that are already taking metformin. The study will last for about 89 weeks.

Conditions

Type 2 Diabetes, Obesity

Talk to us

Study Overview

On this page

Study Details

Study overview

The main purpose of this study is to learn more about the safety and efficacy of investigational tirzepatide doses in participants with Type 2 diabetes and obesity that are already taking metformin. The study will last for about 89 weeks.

A Phase 2, Randomized, Double-blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Investigational Tirzepatide Doses in Participants With Type 2 Diabetes and Obesity

A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity

Condition
Type 2 Diabetes
Intervention / Treatment

-

Contacts and Locations

Tempe

Medical Advancement Centers of Arizona, Tempe, Arizona, United States, 85283

Concord

John Muir Physician Network Research Center, Concord, California, United States, 94520

Sacramento

Care Access - Sacramento, Sacramento, California, United States, 95831

Aurora

Care Access - Aurora, Aurora, Colorado, United States, 80012

Waterbury

Chase Medical Research, LLC, Waterbury, Connecticut, United States, 06708

Miami

Retreat Medical Research, Miami, Florida, United States, 33135

Pembroke Pines

American Research Centers of Florida, Pembroke Pines, Florida, United States, 33027

Norcross

Alta Pharmaceutical Research Center, Norcross, Georgia, United States, 30092

Sandy Springs

AGILE Clinical Research Trials, LLC, Sandy Springs, Georgia, United States, 30328

Chicago

Northwestern University, Chicago, Illinois, United States, 60611

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Have Type 1 Diabetes (T1D), history of ketoacidosis or hyperosmolar state/coma, or any other types of diabetes except T2D.
  • * Have had 1 or more episode of severe hypoglycemia and/or 1 or more episode of hypoglycemia unawareness within 6 months prior to screening.
  • * Are currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema.
  • * Have a prior or planned surgical treatment for obesity.
  • * Use products intended for weight loss including prescription drugs, over the counter (OTC) drugs, and herbal preparations, within 3 months prior to screening.
  • * Have renal impairment measured as estimated glomerular filtration rate (eGFR) \<45 milliliter/min (mL/min)/1.73 m².
  • * Have any of the following cardiovascular (CV) conditions within 2 months prior to screening.
  • * acute myocardial infarction.
  • * cerebrovascular accident (stroke).
  • * unstable angina .
  • * hospitalization due to congestive heart failure, or
  • * coronary artery revascularization.
  • * Have a family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia (MEN) syndrome Type 2.
  • * Have a history of chronic or acute pancreatitis.

Ages Eligible for Study

18 Years to 75 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Eli Lilly and Company,

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), STUDY_DIRECTOR, Eli Lilly and Company

Study Record Dates

2026-10